US IT Spending on Business Intelligence to 2012 Pharmaceutical Technology

(Databook)

Publication Date	April 2007
Publisher	Datamonitor
Product Type	Report
Pages	11
ISBN Number	not applicable
Product Code	DAT04995

Price

£695.00
approximately: $1,036 | €828

PDF

PRINT £745 ($1,111 | €887)

Order above formats by FAX

Summary

Introduction

Although BI in the earlier stages of drug development remains an emergent solution area in the pharmaceutical market, contextual forces such as pipeline productivity pressures and growing generic competition will drive increased spending on BI in the near future.

Scope

Identifies potential growth areas for technology in the pharmaceutical market in the US
Quantifies spending on BI solutions by pharmaceutical segments in the US
Segments IT spending by technology and end-user group

Highlights

The adoption of BI solutions will exhibit strong growth over the next five years.

The Biotech segment will increase their spending on BI solutions more quickly than Big Pharma

BI adoption by clinical end-user groups will demonstrate the most rapid growth compared to R&D, manufacturing and sales & marketing groups.

Reasons to Purchase

Understand the potential opportunity size for BI solutions in the pharmaceutical market.
Identify the BI technology areas in which pharmaceutical companies will invest the most heavily.
Recognize the differences in BI spending across segments of the market and end-user groups.

Content

Overview
CATALYST
SUMMARY
METHODOLOGY
US IT SPENDING ON BUSINESS INTELLIGENCE SOLUTIONS IN PHARMA TO 2012
Introduction
Spending by the US and Europe pharmaceutical industry on BI to 2012
Spending by the US pharmaceutical industry on BI to 2012
Spending on BI solutions by US pharmaceutical sub-segments to 2012
Spending by US Big Pharma on BI solutions by technology to 2012
Spending by US Biotech on BI solutions by technology to 2012
Spending by Global Big Pharma on BI solutions by end-user group to 2012
Spending by Global Biotech on BI solutions by end-user group to 2012

Appendix

Definitions
Further reading
Ask the analyst
Datamonitor consulting
Table 1: Spending by US and Europe pharmaceutical industry on BI solutions to 2012
Table 2: Spending by US pharmaceutical industry on BI solutions to 2012
Table 3: Spending on BI solutions by US pharmaceutical sub-segments to 2012
Table 4: Spending by US Big Pharma on BI solutions by technology
Table 5: Spending by US Big Pharma on BI solutions by technology
Table 6: Spending by Big Pharma on BI solutions by end-user group to 2012 (US & Europe)
Table 7: Spending by Biotech on BI solutions by end-user group to 2012 (US & Europe)
Figure 1: Spending by US and Europe pharmaceutical industry on BI solutions to 2012
Figure 2: Spending by US pharmaceutical industry (Big Pharma & Biotech) on BI solutions to 2012
Figure 3: Spending on BI solutions by US pharmaceutical sub-segments to 2012
Figure 4: Spending by US Big Pharma on BI solutions by technology
Figure 5: Spending by US Biotech on BI solutions by technology
Figure 6: Spending by Big Pharma on BI solutions by end-user group to 2012
Figure 7: Spending by Biotech on BI solutions by end-user group to 2012